Cytora Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.cytora.com
Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200
Phase 1
Active, not recruiting
- Conditions
- Diabetic Foot UlcerDiabetic Foot Ulcer NeuropathicDiabetic Foot
- Interventions
- Biological: hOMSC200Other: Placebo
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Cytora Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT06003530
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Phase 1
Active, not recruiting
- Conditions
- Multiple System AtrophyMSA - Multiple System Atrophy
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Cytora Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05698017
- Locations
- 🇮🇱
Tel-Aviv Sourasky Medical Center (Ichilov), Tel Aviv, Israel
© Copyright 2025. All Rights Reserved by MedPath